BIOMAT Database Logo BIOMAT Database Logo

A phase II study of etoposide, cisplatin plus methotrexate in patients with advanced refractory breast cancer. 1993

M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.
January 1997, European journal of gynaecological oncology,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer.
April 1988, Tumori,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
May 2023, BMC cancer,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.
January 1979, Cancer treatment reports,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Phase II study of oral etoposide for patients with advanced breast cancer.
December 1995, Cancer,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Phase I-II study of high-dose etoposide in patients with refractory breast cancer.
November 1991, Investigational new drugs,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
February 2002, British journal of cancer,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Phase II study with etoposide in previously untreated advanced breast cancer.
January 1989, Cancer chemotherapy and pharmacology,
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
January 1992, European journal of cancer (Oxford, England : 1990),
M Jouve, and T Dorval, and V Mosseri, and T Palangie, and P Beuzeboc, and E Garcia-Giralt, and A Livartowski, and S Scholl, and P Pouillart
Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study.
July 1988, Breast cancer research and treatment,
Copied contents to your clipboard!